BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 20652453)

  • 1. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ohno R
    Curr Hematol Malig Rep; 2010 Oct; 5(4):213-21. PubMed ID: 20652453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Ohno R
    Curr Oncol Rep; 2008 Sep; 10(5):379-87. PubMed ID: 18706265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
    Doki N; Ohashi K; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H
    Pathol Oncol Res; 2014 Jan; 20(1):61-6. PubMed ID: 23821455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
    Ottmann OG; Pfeifer H
    Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Jeha S; Coustan-Smith E; Pei D; Sandlund JT; Rubnitz JE; Howard SC; Inaba H; Bhojwani D; Metzger ML; Cheng C; Choi JK; Jacobsen J; Shurtleff SA; Raimondi S; Ribeiro RC; Pui CH; Campana D
    Cancer; 2014 May; 120(10):1514-9. PubMed ID: 24501014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Xie M; Shi T; Jiang Q; Jia Y; Zhou D; Tong H; Jin J; Zhu HH
    Cancer; 2023 May; 129(10):1523-1536. PubMed ID: 36882308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relapse Prevention with Tyrosine Kinase Inhibitors after Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblast Leukemia: A Systematic Review.
    Warraich Z; Tenneti P; Thai T; Hubben A; Amin H; McBride A; Warraich S; Hannan A; Warraich F; Majhail N; Kalaycio M; Anwer F
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):e55-e64. PubMed ID: 31557532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
    Czyz A; Lewandowski K; Kroll R; Komarnicki M
    Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular response and prognostic factors of patients with Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia treated by imatinib with chemotherapy].
    Wang J; Huang X; Jiang B; Qin Y; Bao L; Jiang H; Chen H; Jia J; Yang S; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):120-5. PubMed ID: 24606652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
    Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of tyrosine kinase inhibitors on allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zhang Y; Feng S
    Leuk Res; 2021 Oct; 109():106647. PubMed ID: 34325192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after allogeneic stem cell transplantation in patients with Philadelphia-positive acute lymphoblastic leukemia: A multicenter retrospective study.
    Guan F; Yang L; Chen Y; Shi J; Song X; Lai X; Lu Y; Liu L; Ouyang G; Zhao Y; Yu J; Xu Y; Lan J; Fu H; Zhao Y; Qiu X; Zhu P; Cai Z; Huang H; Luo Y
    Cancer; 2024 Jun; 130(12):2139-2149. PubMed ID: 38315517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
    Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of imatinib treatment on remission induction and allogeneic stem cell transplantation.
    Kovacsovics T; Maziarz RT
    Curr Oncol Rep; 2006 Sep; 8(5):343-51. PubMed ID: 16901395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Allogeneic hematopoietic stem cell transplantation combined with imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia].
    Cai B; Gao CJ; Li HH; Bo J; Huang WR; Gao L; Sun JF; Ding Y; Wang LL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):173-6. PubMed ID: 20137141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice.
    Yanada M; Naoe T
    Leuk Lymphoma; 2006 Sep; 47(9):1747-53. PubMed ID: 17064984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
    Cai W; Liu B; Xu Y; Chen S; Sun A; He J; Shen H; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):105-9. PubMed ID: 27014978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia.
    Mizuta S; Matsuo K; Yagasaki F; Yujiri T; Hatta Y; Kimura Y; Ueda Y; Kanamori H; Usui N; Akiyama H; Miyazaki Y; Ohtake S; Atsuta Y; Sakamaki H; Kawa K; Morishima Y; Ohnishi K; Naoe T; Ohno R
    Leukemia; 2011 Jan; 25(1):41-7. PubMed ID: 20944676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.